¬x´Â½å¡þ¦ËªFºa°|¯«¸g¬ìÂå®v¡B°ª§J°ö¡þ¦ËªFºa°|°Æ°|ªø
©u¸`©Ê¬y·P¬Ì]±µºØ¦b¥xÆW¤w¦æ¤§¦h¦~¡A¦]¥¼µo¥Í¹L¬Æ»òÄY«°Æ§@¥Î¡A°ê¤H¦¤w®õµM¡u¨É¥Î¡v¡C¦ý¬O·s¬y·P¬O·s¿³¬Ì¯f¡A³¡¤À¬Ì]¬O°ê²£ªº¤Î¹L¥h½Þ¬y·P¬Ì]ªº«á¿ò¯g¡AÃø§KÅýªÀ·|¤j²³¦³¨Ç¿ðºÃ¡C
¬ü°ê1976¦~½Þ¬y·P¬Ì]ª`®g«á¡Aµo¥Í°òÄõ¤Ú·ç¦¡¯gÔ¸s(Guillain-Barre syndrome¡A²ºÙGBS)ªº¤H¤ñ¥±`®Én¦h¨Ç¡A¦Ó³o¤@¦¸ªº·s¬y·P¯f¬r¤S¥¿¦n¦P¬O½Þ¬y·P¯f¬r¸Ìªº¤@«¬¡A©Ò¥H«Ü¦h¤H¹ï·s¬y·P¬Ì]ªº±µºØ¬Û·í¼~Äß¡C
GBS¤SºÙ¡u«æ©Ê¦hµo©Ê¥hÅèÀT¯«¸gª¢(acute inflammatory demyelinating polyradiculoneuropathy)¡v¡A¦¹¯fªº¯S©Ê´N¦p¨ä¦W¡G-«æ©Êµoª¢ªº¤ÏÀ³¯}Ãa©PÃ䯫¸gªºÅèÀT¡A¨Ï¯«¸g±µ¦¬»P¶Ç»¼°T®§µo¥Í»Ùê¡F©Ò¥H¯f¤H¦Ù¦×·|¥Ñ§½³¡¶}©l·U¨Ó·UµL¤O¡AµM«á¦V¨ä¥L³¡¦ì½¯©µ¡A¦P®ÉªÏÅé»·ºÝ·Pı¯«¸g¥\¯à²§±`¡A¦³®É·|¦V¤WÂX®i©Î¦³¯kµh·P¡FÕY§ðÀ»¨ì¦Û¥D¯«¸g©MÆ`¯«¸g¡AÁÙ·|¦³¤ß«ß¤£¾ã¡Bµs¦½¡B¦åÀ£¤£Ã¡BÃC±¯«¸g³Â·ô¡B¤f¾¦¤£²M¡B§]Ã`§xÃøµ¥²{¶H¡C
¬ù20-30%ªº¯f¤H©I§lªº¦Ù¦×¤]·|µL¤O¡A¦³¨Ç¬Æ¦ÜµLªk©I§l¡F¹L¥h¡A¦³2~5%ªº¯f¤H·|¦]¦ÓP©R¡A¦ý¬Oªñ¦~¨Ó¡A¦]¬°¥xÆW¯«¸g¬ìÂå®v´¶¹M¹ï¦¹¯f³£¤w¦³¥R¤Àªº»{ÃÑ¡AÁ{§ÉªºÄµÄ±©Ê«Ü°ª¡A¤S¦³«Ü¦³®ÄªºªvÀø¤èªk¡A¥H¥x¥_ºaÁ`¬°¨Ò¡A¯f¤Hªº¦º¤`²v¬O¡u¹s¡v¡C
³oÓ¯e¯fªº¶EÂ_¤j¦h¨Ì¾a1.¯f¥v¡F2.¯«¸g¾Ç¨ÅéÀˬd¡C¯f¤H·|¦³¹ïºÙ©Êªº¦Ù¦×µL¤O¡B²`³¡¦Ù¸x¤Ï®g®ø¥¢©M·Pı²§±`¡F3.¸£¯áÅè²Gªº³J¥Õ½è¤W¤É¡F4.¯«¸g¶Ç¾É»P¦Ù¹q¹ÏÀˬdªº¤£¥¿±`¡C
³oÓ¯gÔ¸s¦b¶EÂ_½T©w«á¡AÂå®v·|¨Ì¯f¤H±¡ªpªº»´«µ¹¤©¤£¦Pªº³B¸m¡A¸û«ªº±wªÌ¡A¦p§]Ã`§xÃø®É¡A·|µ¹»P»óGºÞÁý¹¡A©I§l§xÃø®É¡A·|´£¨Ñ¨Ï¥Î©I§l¾¹ºû«ù©I§l¡A¯S®íªºªvÀø¥]¬A¦å¼ß¸m´«³N©M§K¬Ì²y³J¥ÕÀR¯ßª`®gµ¥¡C
±qµo¯f¨ì¯f±¡³ÌÄY«¬ù¨â¨ì¤T©P®É¶¡¡A¤§«á¯f±¡º¥ÁÍ¥½w¡AµM«á³vº¥«ì´_¡Fµ´¤j³¡¤À¯f¤Hªº¹w«á¨}¦n¡A¬ù7¦¨ªº¯f¤H¦b1¦~¤º·|«ì´_¨ìªñ¥G¥¿±` ¡A¤j¬ù¦³1¦¨¯f¤H·|¦³¯d¤Uµ{«×¤£µ¥ªºªÏÅéµL¤O¡C
°w¹ï©u¸`©Ê¬y·P¬Ì]¦Ó¨¥¡A®Ú¾Ú¬ü°ê©M^°êªº¬ã¨s¸ê®ÆÅã¥Ü¡A±µºØ¬Ì]©M¿©±wGBSªº¬ÛÃö©Ê¨Ã¥¼½T©w¡F§ÚÌ©IÆ~¡A¦pªG¥Á²³¦b±µºØ¬Ì]«á4¦Ü6©P¤º¡A¦³¥ô¦ó³¡¦ìªº¦Ù¦×³vº¥ÅܱoµL¤O¡B¨Ã¦³ªÏÅé³Â¤ì¯kµhµ¥²{¶H®É¡A½Ð¾¨¦±µ¨ü¯«¸g¬ìÂå®vªº¶E¹î¡AY¯à¦´Áµo²{»PªvÀø¡AGBS³oÓ¯gÔ¸sªº¦MÀI©Ê¤]·|¤j´Tªº¤U°¡A«O«ùĵı¦Ó¤£¹L«×ºò±i¡A¤~¬O±¹ï·s¬y·P¬Ì]ª`®gªº¥¿½TÆ[©À¡C
